期刊
JOURNAL OF CLINICAL INVESTIGATION
卷 118, 期 1, 页码 195-204出版社
AMER SOC CLINICAL INVESTIGATION INC
DOI: 10.1172/JCI33139
关键词
-
资金
- NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL080706] Funding Source: NIH RePORTER
- NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM054597] Funding Source: NIH RePORTER
- NHLBI NIH HHS [R01 HL080706, R01 HL080706-11, R01 HL080706-13, R01 HL080706-12, R01 HL080706-10] Funding Source: Medline
- NIGMS NIH HHS [R01 GM054597] Funding Source: Medline
Atherosclerosis is an inflammatory disease that is associated with monocyte recruitment and subsequent differentiation into lipid-laden macrophages at sites of arterial lesions, leading to the development of atherosclerotic plaques. PLC is a key member of signaling pathways initiated by G protein-coupled ligands in macrophages. However, the role of this enzyme in the regulation of macrophage function is not known. Here, we studied macrophages from mice lacking PLC beta 2, PLC beta 3, or both PLC isoforms and found that PLC beta 3 is the major functional PLC beta isoform in murine macrophages. Although PLC beta 3 deficiency did not affect macrophage migration, adhesion, or phagocytosis, it resulted in macrophage hypersensitivity to multiple inducers of apoptosis. PLC beta 3 appeared to regulate this sensitivity via PKC-dependent upregulation of Bcl-XL. The significance of PLC beta signaling in vivo was examined using the apoE-deficient mouse model of atherosclerosis. Mice lacking both PLC beta 3 and apoE exhibited fewer total macrophages and increased macrophage apoptosis in atherosclerotic lesions, as well as reduced atherosclerotic lesion size when compared with mice lacking only apoE. These results demonstrate what we believe to be a novel role for PLC activity in promoting macrophage survival in atherosclerotic plaques and identify PLC beta 3 as a potential target for treatment of atherosclerosis.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据